Free Newsletter
Too much off-label regulation?
The Internet is buzzing about a Wall Street Journal op-ed piece in which ex-FDA deputy commissioner Scott Gottlieb (photo) championed the sort of off-label promotions that make regulators crazy. Gottlieb cited a couple of cases in which drug makers have paid multi-million dollar fines for pushing meds in non-FDA-approved directions. The whole off-label promotion ban is wrong, Gottlieb says, and it hurts patients who might benefit from off-label uses if their docs only knew.
Yet, as the WSJ Health Blog points out, off-label marketing isn't allowed for a reason. Some of it amounts to cherry-picking studies that support new uses for a drug. Marketers often ignore the trials that conclude otherwise. But has the FDA gone too far in policing the practice? Debate is likely to continue.
- read the Health Blog item
- here's the Pharmalot report
- read Gottlieb's original op-ed
Related Articles:
Rep decries off-label marketing "loophole." Report
New warning for off-label Fentora. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: